LU87334A1 - Suppositoires a base de calcitonine - Google Patents

Suppositoires a base de calcitonine Download PDF

Info

Publication number: LU87334A1
Authority: LU; Luxembourg
Prior art keywords: calcitonin; suppository; suppositories; acid; taurocholic acid
Prior art date: 1987-09-15

Application number

LU87334A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-15

Filing date

1988-09-12

Publication date

1989-07-07

1987-09-15 Priority claimed from GB878721700A external-priority patent/GB8721700D0/en

1988-01-29 Priority claimed from GB888801991A external-priority patent/GB8801991D0/en

1988-03-03 Priority claimed from GB888805068A external-priority patent/GB8805068D0/en

1988-09-12 Application filed by Sandoz Sa filed Critical Sandoz Sa

1989-07-07 Publication of LU87334A1 publication Critical patent/LU87334A1/fr

Links

239000000829 suppository Substances 0.000 title claims description 66
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims description 49
102000055006 Calcitonin Human genes 0.000 title claims description 35
108060001064 Calcitonin Proteins 0.000 title claims description 35
229960004015 calcitonin Drugs 0.000 title claims description 33
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 23
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 20
239000000546 pharmaceutical excipient Substances 0.000 claims description 18
108010068072 salmon calcitonin Proteins 0.000 claims description 15
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 12
238000010521 absorption reaction Methods 0.000 claims description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
159000000000 sodium salts Chemical class 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims description 2
229940045644 human calcitonin Drugs 0.000 claims description 2
JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
239000008187 granular material Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 5
229940124532 absorption promoter Drugs 0.000 description 5
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 5
238000007906 compression Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
230000006835 compression Effects 0.000 description 3
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 3
229910052500 inorganic mineral Chemical class 0.000 description 3
239000011707 mineral Chemical class 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
-1 polymeric acids Chemical class 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
229940038773 trisodium citrate Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
240000004658 Medicago sativa Species 0.000 description 1
235000010624 Medicago sativa Nutrition 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
159000000009 barium salts Chemical class 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940069078 citric acid / sodium citrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000003804 extraction from natural source Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Bakery Products And Manufacturing Methods Therefor (AREA)

LU87334A 1987-09-15 1988-09-12 Suppositoires a base de calcitonine LU87334A1 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB878721700A GB8721700D0 (en)	1987-09-15	1987-09-15	Organic compounds
GB8721700		1987-09-15
GB8801991		1988-01-29
GB888801991A GB8801991D0 (en)	1988-01-29	1988-01-29	Improvements in/relating to organic compounds
GB888805068A GB8805068D0 (en)	1988-03-03	1988-03-03	Improvements in/relating to organic compounds
GB8805068		1988-03-03

Publications (1)

Publication Number	Publication Date
LU87334A1 true LU87334A1 (fr)	1989-07-07

Family

ID=27263605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87334A LU87334A1 (fr)	1987-09-15	1988-09-12	Suppositoires a base de calcitonine

Country Status (26)

Country	Link
US (1)	US5149537A (no)
JP (1)	JPH01228919A (no)
KR (1)	KR970003052B1 (no)
AT (1)	AT396424B (no)
AU (1)	AU614769B2 (no)
BE (1)	BE1001937A3 (no)
CA (1)	CA1330417C (no)
CH (1)	CH677320A5 (no)
CY (1)	CY1763A (no)
DE (1)	DE3830245A1 (no)
DK (1)	DK509888A (no)
ES (1)	ES2012119A6 (no)
FI (1)	FI87889C (no)
FR (1)	FR2620331B1 (no)
GB (1)	GB2209670B (no)
HK (1)	HK19394A (no)
HU (1)	HU203204B (no)
IL (1)	IL87747A (no)
LU (1)	LU87334A1 (no)
MY (1)	MY103611A (no)
NL (1)	NL8802274A (no)
NO (1)	NO175518C (no)
NZ (1)	NZ226162A (no)
PH (1)	PH24766A (no)
PT (1)	PT88491B (no)
SE (1)	SE8803222L (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991013601A1 (en) *	1990-03-15	1991-09-19	Rhône-Poulenc Rorer International (Holdings) Inc.	Calcitonin suppository formulations
GB9013448D0 (en) *	1990-06-15	1990-08-08	Sandoz Ltd	Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
DE4222647A1 (de) *	1991-07-15	1993-01-21	Sandoz Ag	Peptid-zubereitungen
US5262172A (en) *	1992-06-19	1993-11-16	Digestive Care Inc.	Compositions of gastric acid-resistant microspheres containing buffered bile acids
JPH0776527A (ja) *	1993-06-28	1995-03-20	Hayashibara Biochem Lab Inc	半固形製剤とその製造方法
US7135191B2 (en) *	1997-09-04	2006-11-14	Zsolt Istvan Hertelendy	Urogenital or anorectal transmucosal vaccine delivery system
US7772220B2 (en) *	2004-10-15	2010-08-10	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
DE69924740T2 (de)	1998-07-24	2005-09-01	Yoo, Seo Hong	Klare wässrige lösungen enthaltend gallensäuren
US20050158408A1 (en) *	1998-07-24	2005-07-21	Yoo Seo H.	Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) *	1998-07-24	2007-12-04	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
CN100558407C (zh) *	2000-02-04	2009-11-11	柳署弘	制备含有胆汁酸的澄清水溶液剂型
US7145125B2 (en)	2003-06-23	2006-12-05	Advanced Optical Technologies, Llc	Integrating chamber cone light using LED sources
PL2316473T3 (pl)	2003-07-23	2014-05-30	Novartis Ag	Zastosowanie kalcytoniny w chorobie zwyrodnieniowej stawów
EP1789057B1 (en) *	2004-08-30	2010-02-24	Seo Hong Yoo	Neuroprotective effect of solubilized udca in focal ischemic model
AU2005295541B2 (en) *	2004-10-15	2011-02-17	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
CA2585471A1 (en) *	2004-11-01	2006-05-11	Seo Hong Yoo	Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US8143314B1 (en)	2007-09-13	2012-03-27	Robert Carl Stover	Methods and formulations for treating ineffective or decreased esophageal motility
KR102287352B1 (ko) *	2015-06-30	2021-08-06	(주)아모레퍼시픽	화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH211204A (de) *	1938-12-13	1940-08-31	Chem Ind Basel	Verfahren zur Herstellung einer Suppositoriengrundmasse.
US4164573A (en) *	1975-06-13	1979-08-14	Galinsky Alvin M	Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
ATE8584T1 (de) *	1980-01-16	1984-08-15	Hans Georg Prof. Dr. Weder	Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
JPS56118013A (en) *	1980-02-25	1981-09-16	Teijin Ltd	Calcitonin pharmaceutical and its preparation
JPS56138110A (en) *	1980-03-28	1981-10-28	Teijin Ltd	Suppository containing citric acid or salt thereof
JPS56138115A (en) *	1980-03-31	1981-10-28	Teijin Ltd	Suppository containing acidic amino acid or derivative thereof
DE3171774D1 (en) *	1980-03-31	1985-09-19	Teijin Ltd	Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
IL64397A0 (en) *	1981-01-07	1982-02-28	Weder Hans G	Process for the preparation of liposomal medicaments
IL70489A0 (en) *	1982-12-29	1984-03-30	Armour Pharma	Pharmaceutical compositions containing calcitonin
US4801577A (en) *	1987-02-05	1989-01-31	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
IT1222734B (it) *	1987-09-25	1990-09-12	Scalvo S P A	Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina

1988
- 1988-09-01 HU HU884522A patent/HU203204B/hu not_active IP Right Cessation
- 1988-09-06 DE DE3830245A patent/DE3830245A1/de not_active Withdrawn
- 1988-09-08 BE BE8801035A patent/BE1001937A3/fr not_active IP Right Cessation
- 1988-09-08 FR FR888811852A patent/FR2620331B1/fr not_active Expired - Lifetime
- 1988-09-12 PH PH37535A patent/PH24766A/en unknown
- 1988-09-12 LU LU87334A patent/LU87334A1/fr unknown
- 1988-09-12 CH CH3399/88A patent/CH677320A5/de not_active IP Right Cessation
- 1988-09-13 CA CA000577213A patent/CA1330417C/en not_active Expired - Fee Related
- 1988-09-13 NO NO884053A patent/NO175518C/no unknown
- 1988-09-13 SE SE8803222A patent/SE8803222L/xx not_active Application Discontinuation
- 1988-09-13 DK DK509888A patent/DK509888A/da not_active Application Discontinuation
- 1988-09-13 MY MYPI88001024A patent/MY103611A/en unknown
- 1988-09-13 PT PT88491A patent/PT88491B/pt not_active IP Right Cessation
- 1988-09-13 GB GB8821429A patent/GB2209670B/en not_active Expired - Lifetime
- 1988-09-13 AU AU22175/88A patent/AU614769B2/en not_active Ceased
- 1988-09-13 FI FI884191A patent/FI87889C/fi not_active IP Right Cessation
- 1988-09-13 NZ NZ226162A patent/NZ226162A/en unknown
- 1988-09-14 AT AT0224788A patent/AT396424B/de not_active IP Right Cessation
- 1988-09-14 JP JP63231394A patent/JPH01228919A/ja active Pending
- 1988-09-14 KR KR1019880011875A patent/KR970003052B1/ko not_active Expired - Lifetime
- 1988-09-14 IL IL87747A patent/IL87747A/xx not_active IP Right Cessation
- 1988-09-15 ES ES8802832A patent/ES2012119A6/es not_active Expired - Lifetime
- 1988-09-15 NL NL8802274A patent/NL8802274A/nl not_active Application Discontinuation
1991
- 1991-11-14 US US07/791,841 patent/US5149537A/en not_active Expired - Fee Related
1994
- 1994-03-10 HK HK193/94A patent/HK19394A/xx unknown
- 1994-07-15 CY CY176394A patent/CY1763A/en unknown

Also Published As

Publication number	Publication date
HK19394A (en)	1994-03-18
FI884191L (fi)	1989-03-16
FR2620331B1 (fr)	1991-11-08
GB2209670B (en)	1991-05-08
NO884053D0 (no)	1988-09-13
AT396424B (de)	1993-09-27
JPH01228919A (ja)	1989-09-12
NO175518C (no)	1994-10-26
FI87889C (fi)	1993-03-10
GB2209670A (en)	1989-05-24
DK509888D0 (da)	1988-09-13
SE8803222D0 (sv)	1988-09-13
SE8803222L (sv)	1989-03-16
PT88491A (pt)	1988-10-01
HUT47864A (en)	1989-04-28
KR890004680A (ko)	1989-05-09
AU614769B2 (en)	1991-09-12
CH677320A5 (no)	1991-05-15
DK509888A (da)	1989-03-16
HU203204B (en)	1991-06-28
NO175518B (no)	1994-07-18
CY1763A (en)	1994-07-15
PT88491B (pt)	1992-11-30
KR970003052B1 (ko)	1997-03-14
NZ226162A (en)	1991-03-26
ATA224788A (de)	1993-01-15
MY103611A (en)	1993-08-28
GB8821429D0 (en)	1988-10-12
FI884191A0 (fi)	1988-09-13
BE1001937A3 (fr)	1990-04-17
ES2012119A6 (es)	1990-03-01
US5149537A (en)	1992-09-22
AU2217588A (en)	1989-04-20
CA1330417C (en)	1994-06-28
FI87889B (fi)	1992-11-30
PH24766A (en)	1990-10-01
DE3830245A1 (de)	1989-03-30
FR2620331A1 (fr)	1989-03-17
IL87747A0 (en)	1989-02-28
NL8802274A (nl)	1989-04-03
NO884053L (no)	1989-03-16
IL87747A (en)	1992-05-25

Publication	Publication Date	Title
BE1001937A3 (fr)	1990-04-17	Suppositoire a base de calcitonine.
EP1467724B1 (fr)	2006-05-03	Composition pharmaceutique orodispersible d'agomelatine
FR2537980A1 (fr)	1984-06-22	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
HU211544A9 (en)	1995-12-28	Transdermal composition
FR2642650A1 (fr)	1990-08-10	Nouvelles compositions pharmaceutiques a base de cyclosporines
FR2764800A1 (fr)	1998-12-24	Composition pharmaceutique solide contenant des derives de benzofuranne
CA2123232C (fr)	2005-02-15	Compositions pharmaceutiques a base d'ebastine ou de ses analogues
BE895724A (fr)	1983-07-28	Nouvelle utilisation therapeutique de la dihydrocyclosporine d
WO2018197731A1 (fr)	2018-11-01	Extrait de 20-hydroxyecdysone de qualité pharmaceutique, son utilisation et sa préparation
CA2004092A1 (fr)	1990-05-29	Amincissants topiques contenant des derives cafeines carboxyliques neutralises par des bases organiques et preparations utiles dans le traitement de la cellulite
EP0601911B1 (fr)	1997-04-09	Acylaminoacides obtenus par l'acylation d'hydrolysats de protéines et compositions anti-microbiennes, antiparasitaires ou cosmétiques en contenant
LU86901A1 (fr)	1987-12-16	Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale
FR2723093A1 (fr)	1996-02-02	Esters d'acyle d'acides amines achiraux du glanciclovir
JPH08508984A (ja)	1996-09-24	経口投与用シクロスポリン含有新規製剤
BE1005115A5 (fr)	1993-04-27	Compositions pharmaceutiques contenant des derives de furanne.
FR2742660A1 (fr)	1997-06-27	Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
EP0846688A1 (fr)	1998-06-10	Nouveaux dérivés de l'imidazoline ayant une affinité pour les récepteurs aux imidazolines
FR2510112A1 (fr)	1983-01-28	Nouveaux derives du 2-oxo-pyrid-3-yl ou piperidin-3-yl indole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
BE898430A (fr)	1984-06-12	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation.
FR2705895A1 (fr)	1994-12-09	Comprimés médicamenteux exempts d'agent lubrifiant.
EP1358159B1 (fr)	2009-07-22	Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
FR2534808A1 (fr)	1984-04-27	Composition antivirale contenant du 2-(4-chlorophenoxymethyl)-3,3-dimethyl-1-(1,2,4-triazole-1-yl)-2-butanol
FR2555048A1 (fr)	1985-05-24	Procede de fabrication de compositions de nifedipine et nouveaux produits ainsi obtenus
FR2623090A1 (fr)	1989-05-19	Compositions pharmaceutiques contenant une calcitonine
FR2673105A1 (fr)	1992-08-28	Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.